Evidence map›Paper›PMID 35308199›Full record

ArticleFrontiers in pharmacology2022

Immunotherapeutic Value of MAP1LC3C and Its Candidate FDA-Approved Drugs Identified by Pan-Cancer Analysis, Virtual Screening and Sensitivity Analysis.

Xudong Zhang, Kunhang Li, Shiyu Zhong, Shengyu Liu, Tao Liu, Lishuai Li, Shuo Han, Qingqing Zhai, Nan Bao, Xin Shi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Xudong ZhangDepartment of Neurosurgery, The Fourth Hospital of China Medical University, Shenyang, China.
Kunhang LiDepartment of Neurosurgery, The Fourth Hospital of China Medical University, Shenyang, China.
Shiyu ZhongDepartment of Neurosurgery, The Fourth Hospital of China Medical University, Shenyang, China.
Shengyu LiuDepartment of Neurosurgery, The Fourth Hospital of China Medical University, Shenyang, China.
Tao LiuDepartment of Neurosurgery, The Fourth Hospital of China Medical University, Shenyang, China.
Lishuai LiDepartment of Neurosurgery, The Fourth Hospital of China Medical University, Shenyang, China.
Shuo HanDepartment of Neurosurgery, The Fourth Hospital of China Medical University, Shenyang, China.
Qingqing ZhaiSchool of Management, Shanghai University, Shanghai, China.
Nan BaoCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
Xin ShiSchool of Maths and Information Science, Shangdong Technology and Business University, Yantai, China.
Yijun BaoDepartment of Neurosurgery, The Fourth Hospital of China Medical University, Shenyang, China.
China Medical University · CNFourth Affiliated Hospital of China Medical University · CNManchester Metropolitan University · GBNortheastern University · CNShanghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immunotherapymolecualr dockingpan-cancer analysisprognosistumor microenvironment

Identifiers

PMID35308199
PMCPMC8929514
OpenAlexW4214842329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.